Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;9(3):e1900925.
doi: 10.1002/adhm.201900925. Epub 2020 Jan 1.

Human Tumor-Lymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells

Affiliations

Human Tumor-Lymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells

Jose M Ayuso et al. Adv Healthc Mater. 2020 Feb.

Abstract

Breast tumor progression is a complex process involving intricate crosstalk between the primary tumor and its microenvironment. In the context of breast tumor-lymphatic interactions, it is unclear how breast cancer cells alter the gene expression of lymphatic endothelial cells and how these transcriptional changes potentiate lymphatic dysfunction. Thus, there is a need for in vitro lymphatic vessel models to study these interactions. In this work, a tumor-lymphatic microfluidic model is developed to study the differential conditioning of lymphatic vessels by estrogen receptor-positive (i.e., MCF7) and triple-negative (i.e., MDA-MB-231) breast cancer cells. The model consists of a lymphatic endothelial vessel cultured adjacently to either MCF7 or MDA-MB-231 cells. Quantitative transcriptional analysis reveals expression changes in genes related to vessel growth, permeability, metabolism, hypoxia, and apoptosis in lymphatic endothelial cells cocultured with breast cancer cells. Interestingly, these changes are different in the MCF7-lymphatic cocultures as compared to the 231-lymphatic cocultures. Importantly, these changes in gene expression correlate to functional responses, such as endothelial barrier dysfunction. These results collectively demonstrate the utility of this model for studying breast tumor-lymphatic crosstalk for multiple breast cancer subtypes.

Keywords: breast cancer; estrogen receptor-positive; lymphatic; microfluidic; triple-negative.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

David J. Beebe is a board member and stockowner of Tasso, Inc. and a stockowner of Bellbrook Labs, LLC. David J. Beebe is a founder, stockowner, and consultant of Salus Discovery LLC. David J. Beebe is an advisor and stockowner of Lynx Biosciences, LLC, Onexio Biosystems, LLC, and Stacks to the Future, LLC. David J. Beebe holds equity in Bellbrook Labs, LLC, Tasso Inc., Salus Discovery LLC, Stacks to the Future, LLC and Onexio Biosystems, LLC.

Figures

Figure 1.
Figure 1.
Concept and operation of the breast tumor-lymphatic microfluidic device. A) The device consists of two polydimethylsiloxane (PDMS) layers. The bottom layer comprises a chamber and microchannels for suspending two adjacent lumen rods. The top layer contains the ports for fluid exchange. Cell culture in the device allows the formation of a lumen lined with primary human lymphatic endothelial cells (HLECs) and a second lumen filled with breast cancer cells. B) Illustration of key steps in the operation of the co-culture device. C) Representative confocal image of a 3D lymphatic vessel. D-F) Representative images of vessel monoculture, co-culture with MCF7 cells (in yellow), and co-culture with MDA-MB-231 cells (in green) in the device.
Figure 2.
Figure 2.
Influence of MCF7 and MDA-MB-231 cells on lymphatic lumen gene expression. A-H) Lymphatic endothelial lumens were co-cultured alone and in the presence of MCF7 or MDA-MB-231 cells for 24 hours. Then, lymphatic endothelial cells were isolated and gene expression was analyzed. The graphs show the genes that were differentially expressed when lymphatic endothelial cells were co-cultured with MCF7 (blue columns) or MDA-MB-231 (red columns). I) Clustergram showing the changes in all the genes analyzed. The clustering algorithm revealed the co-culture with MCF7 led to a more different gene expression signature. J) Radar plot showing the number of genes affected in HLECs by the presence of MCF7 (in blue) and MAD-MB-231 (in red).
Figure 3.
Figure 3.
Endothelial cell coverage and lymphangiogenic sprouting. A) Confocal images showing the middle plane of lymphatic vessels in monoculture and co-culture with MCD7 and MDA-MB-231 cells. B) Z-projected images of vessels in monoculture and co-culture with MCF7 and MDA-MB-231 cells. C) Quantification of cell coverage for each culture condition showing an average percentage of cell coverage >99% for all conditions. D) Crosstalk with the breast cancer cells induced lymphangiogenic sprouting in the vessels. There were no observable sprouts in the monoculture control. Three individual vessels (n = 3) were measured for each culture condition to determine the average permeability value (mean ± s.d.).
Figure 4.
Figure 4.
Vessel permeability in monoculture and co-culture. Representative images at t = 0 min. and t = 10 min. for diffusion of A) a glucose analog and B) 70 kDa dextran. Dashed boxes indicate the region of interest used for measuring diffusion profiles. Dashed lines indicate the walls of the vessel. C) Diffusion profiles at t = 10 min. for monoculture and co-culture conditions. D) Glucose and dextran permeability values calculated for monoculture and co-culture conditions. MCF7-conditioned vessels were the leakiest in comparison to MDA-MB-231-conditioned vessels and monoculture controls. Three individual vessels (n = 3) were measured for each culture condition to determine the average permeability value (mean ± s.d.).

References

    1. Joyce JA, Pollard JW, Nat Rev Cancer 2009, 9, 239. - PMC - PubMed
    1. Tang C, Wang P, Li X, Zhao B, Yang H, Yu H, Li C, Plos One 2017, 12, e0182953; - PMC - PubMed
    2. Truong PT, Vinh-Hung V, Cserni G, Woodward WA, Tai P, Vlastos G, Eur J Cancer 2008, 44, 1670; - PubMed
    3. Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Ames FC, Babiera GV, Cancer 2004, 101, 1330. - PubMed
    1. Ran S, Volk L, Hall K, Flister MJ, Pathophysiology : the official journal of the International Society for Pathophysiology 2010, 17, 229. - PMC - PubMed
    1. Alitalo A, Detmar M, Oncogene 2012, 31, 4499. - PubMed
    1. Dieterich LC, Ikenberg K, Cetintas T, Kapaklikaya K, Hutmacher C, Detmar M, Frontiers in immunology 2017, 8, 66; - PMC - PubMed
    2. Swartz MA, Cancer Immunol Res 2014, 2, 701. - PubMed

Publication types

MeSH terms